Published in Antimicrob Agents Chemother on July 01, 1995
DNA gyrase, topoisomerase IV, and the 4-quinolones. Microbiol Mol Biol Rev (1997) 9.69
DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance. Proc Natl Acad Sci U S A (1997) 2.99
Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene. Antimicrob Agents Chemother (1996) 2.42
Fluoroquinolone action against mycobacteria: effects of C-8 substituents on growth, survival, and resistance. Antimicrob Agents Chemother (1998) 2.35
Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group. Antimicrob Agents Chemother (1999) 2.16
Killing of Staphylococcus aureus by C-8-methoxy fluoroquinolones. Antimicrob Agents Chemother (1998) 1.86
Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother (2001) 1.77
Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother (2004) 1.62
Fluoroquinolone action against clinical isolates of Mycobacterium tuberculosis: effects of a C-8 methoxyl group on survival in liquid media and in human macrophages. Antimicrob Agents Chemother (1999) 1.56
Selection of Streptococcus pneumoniae mutants having reduced susceptibility to moxifloxacin and levofloxacin. Antimicrob Agents Chemother (2002) 1.46
Comparison of recalcitrance to ciprofloxacin and levofloxacin exhibited by Pseudomonas aeruginosa bofilms displaying rapid-transport characteristics. Antimicrob Agents Chemother (1997) 1.46
Mutation in the DNA gyrase A Gene of Escherichia coli that expands the quinolone resistance-determining region. Antimicrob Agents Chemother (2001) 1.40
Enhancement of fluoroquinolone activity by C-8 halogen and methoxy moieties: action against a gyrase resistance mutant of Mycobacterium smegmatis and a gyrase-topoisomerase IV double mutant of Staphylococcus aureus. Antimicrob Agents Chemother (2001) 1.20
Relationships among ciprofloxacin, gatifloxacin, levofloxacin, and norfloxacin MICs for fluoroquinolone-resistant Escherichia coli clinical isolates. Antimicrob Agents Chemother (2008) 1.11
Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model. Antimicrob Agents Chemother (2003) 1.03
Improved antimicrobial activity of DU-6859a, a new fluoroquinolone, against quinolone-resistant Klebsiella pneumoniae and Enterobacter cloacae isolates with alterations in GyrA and ParC proteins. Antimicrob Agents Chemother (1997) 0.92
Cloning, expression, and enzymatic characterization of Pseudomonas aeruginosa topoisomerase IV. Antimicrob Agents Chemother (1999) 0.91
Specific patterns of gyrA mutations determine the resistance difference to ciprofloxacin and levofloxacin in Klebsiella pneumoniae and Escherichia coli. BMC Infect Dis (2013) 0.89
Propensity of fluoroquinolones with different moieties at position 8 to cause resistance development in clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother (2001) 0.81
Helicobacter pylori eradication by sitafloxacin-lansoprazole combination and sitafloxacin pharmacokinetics in Mongolian gerbils and its in vitro activity and resistance development. Antimicrob Agents Chemother (2011) 0.78
Contribution of the C-8-methoxy group of gatifloxacin to inhibition of type II topoisomerases of Staphylococcus aureus. Antimicrob Agents Chemother (2002) 0.75
Combinatorially-generated library of 6-fluoroquinolone analogs as potential novel antitubercular agents: a chemometric and molecular modeling assessment. J Mol Model (2011) 0.75
DNA gyrase: an enzyme that introduces superhelical turns into DNA. Proc Natl Acad Sci U S A (1976) 17.42
Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother (1990) 11.71
Interaction between DNA and an Escherichia coli protein omega. J Mol Biol (1971) 11.03
Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol (1994) 7.89
New topoisomerase essential for chromosome segregation in E. coli. Cell (1990) 7.19
Quinolone resistance-determining region in the DNA gyrase gyrB gene of Escherichia coli. Antimicrob Agents Chemother (1991) 6.19
Resistance of Pseudomonas aeruginosa PAO to nalidixic acid and low levels of beta-lactam antibiotics: mapping of chromosomal genes. Antimicrob Agents Chemother (1982) 5.67
Mutations producing resistance to norfloxacin in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1987) 4.96
Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother (1992) 4.43
4-Quinolone resistance mutations in the DNA gyrase of Escherichia coli clinical isolates identified by using the polymerase chain reaction. Antimicrob Agents Chemother (1991) 4.35
Mechanism of inhibition of DNA gyrase by quinolone antibacterials: a cooperative drug--DNA binding model. Biochemistry (1989) 3.09
Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant. J Bacteriol (1987) 3.04
Ciprofloxacin resistance in coagulase-positive and -negative staphylococci: role of mutations at serine 84 in the DNA gyrase A protein of Staphylococcus aureus and Staphylococcus epidermidis. Antimicrob Agents Chemother (1991) 2.80
Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother (1994) 2.76
Mechanism of action of quinolones against Escherichia coli DNA gyrase. Antimicrob Agents Chemother (1993) 2.48
Cloning and nucleotide sequence of Pseudomonas aeruginosa DNA gyrase gyrA gene from strain PAO1 and quinolone-resistant clinical isolates. Antimicrob Agents Chemother (1994) 2.47
Proportion of DNA gyrase mutants among quinolone-resistant strains of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1990) 2.17
Escherichia coli DNA topoisomerase III: purification and characterization of a new type I enzyme. Biochemistry (1984) 1.63
Mechanisms of high-level resistance to quinolones in urinary tract isolates of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1994) 1.60
Use of a broad-host-range gyrA plasmid for genetic characterization of fluoroquinolone-resistant gram-negative bacteria. Antimicrob Agents Chemother (1991) 1.42
A pleiotropic, posttherapy, enoxacin-resistant mutant of Pseudomonas aeruginosa. Antimicrob Agents Chemother (1992) 1.37
Development of quinolone-imipenem cross resistance in Pseudomonas aeruginosa during exposure to ciprofloxacin. Antimicrob Agents Chemother (1990) 1.36
In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises. Antimicrob Agents Chemother (1991) 1.35
Inhibitory effects of quinolones on pro- and eucaryotic DNA topoisomerases I and II. Antimicrob Agents Chemother (1990) 1.25
Activity of new quinolones against ciprofloxacin-resistant staphylococci. Antimicrob Agents Chemother (1991) 1.21
Ciprofloxacin-induced, low-level resistance to structurally unrelated antibiotics in Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother (1993) 1.06
Drug resistance of Pseudomonas aeruginosa with special reference to new quinolones. Antibiot Chemother (1971) (1991) 1.01
(Fluorocyclopropyl)quinolones. 2. Synthesis and Stereochemical structure-activity relationships of chiral 7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-(2-fluorocyclopropyl)quinolone antibacterial agents. J Med Chem (1994) 0.85
KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res (1999) 40.62
Analysis of the mouse transcriptome based on functional annotation of 60,770 full-length cDNAs. Nature (2002) 28.79
A Toll-like receptor recognizes bacterial DNA. Nature (2000) 26.34
Functional annotation of a full-length mouse cDNA collection. Nature (2001) 23.61
In vitro and in vivo activity of DL-8280, a new oxazine derivative. Antimicrob Agents Chemother (1982) 21.31
Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity (1999) 17.40
Regulated expression of a gene encoding a nuclear factor, IRF-1, that specifically binds to IFN-beta gene regulatory elements. Cell (1988) 9.04
Cutting edge: TLR2-deficient and MyD88-deficient mice are highly susceptible to Staphylococcus aureus infection. J Immunol (2000) 6.61
T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. Nature (2000) 6.49
Structurally similar but functionally distinct factors, IRF-1 and IRF-2, bind to the same regulatory elements of IFN and IFN-inducible genes. Cell (1989) 6.11
Delineating developmental and metabolic pathways in vivo by expression profiling using the RIKEN set of 18,816 full-length enriched mouse cDNA arrays. Proc Natl Acad Sci U S A (2001) 6.07
Typing hepatitis C virus by polymerase chain reaction with type-specific primers: application to clinical surveys and tracing infectious sources. J Gen Virol (1992) 5.93
Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. J Immunol (2001) 5.27
Identification and characterization of inhibitors of multidrug resistance efflux pumps in Pseudomonas aeruginosa: novel agents for combination therapy. Antimicrob Agents Chemother (2001) 5.23
T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity (2001) 4.62
Antimicrobial activity of DU-6859, a new potent fluoroquinolone, against clinical isolates. Antimicrob Agents Chemother (1992) 4.43
Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur J Immunol (1988) 4.20
In vitro activity of DR-3355, an optically active ofloxacin. Antimicrob Agents Chemother (1988) 4.03
Isolation of human rotavirus in cell cultures: brief report. Arch Virol (1981) 3.83
Purification and properties of DNA gyrase from a fluoroquinolone-resistant strain of Escherichia coli. Antimicrob Agents Chemother (1986) 3.69
Biochemical properties of beta-lactamase produced by Flavobacterium odoratum. Antimicrob Agents Chemother (1985) 3.62
Defining the functions of trans-SNARE pairs. Nature (1998) 3.52
The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity (2001) 3.52
Propensity of ectopic liver to hepatocarcinogenesis: case reports and a review of the literature. Hepatology (1999) 3.29
Breast cancer after exposure to the atomic bombings of Hiroshima and Nagasaki. N Engl J Med (1968) 3.29
Endotoxin-induced maturation of MyD88-deficient dendritic cells. J Immunol (2001) 3.26
Induction of endogenous IFN-alpha and IFN-beta genes by a regulatory transcription factor, IRF-1. Nature (1989) 3.25
Calcium movements, distribution, and functions in smooth muscle. Pharmacol Rev (1997) 3.23
Dentatorubral and pallidoluysian atrophy expansion of an unstable CAG trinucleotide on chromosome 12p. Nat Genet (1994) 3.17
Evidence for a nuclear factor(s), IRF-1, mediating induction and silencing properties to human IFN-beta gene regulatory elements. EMBO J (1988) 3.11
Some properties of subunits of DNA gyrase from Pseudomonas aeruginosa PAO1 and its nalidixic acid-resistant mutant. J Bacteriol (1987) 3.04
Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res (1996) 2.86
Activity of beta-lactamase produced by Bacteroides fragilis against newly introduced cephalosporins. Antimicrob Agents Chemother (1980) 2.76
Comparison of inhibition of Escherichia coli topoisomerase IV by quinolones with DNA gyrase inhibition. Antimicrob Agents Chemother (1994) 2.76
Synthesis and antibacterial activities of optically active ofloxacin. Antimicrob Agents Chemother (1986) 2.74
Identification of various serovar strains of Mycobacterium avium complex by using DNA probes specific for Mycobacterium avium and Mycobacterium intracellulare. J Clin Microbiol (1990) 2.73
The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients. Leukemia (2005) 2.71
Antagonistic action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/.NO through a radical reaction. Biochemistry (1993) 2.70
Change in receptor-binding specificity of recent human influenza A viruses (H3N2): a single amino acid change in hemagglutinin altered its recognition of sialyloligosaccharides. Virology (2000) 2.70
Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res (1991) 2.70
Frequency of a 22q11 deletion in patients with conotruncal cardiac malformations: a prospective study. Eur J Pediatr (1995) 2.66
Fas ligand in human serum. Nat Med (1996) 2.53
Effect of N-formimidoyl thienamycin (MK0787) on beta-lactamases and activity against beta-lactamase-producing strains. Antimicrob Agents Chemother (1980) 2.53
Studies of novel transducing variants of lambda: dispensability of genes N and Q. Virology (1969) 2.44
Salt and pH-dependent changes of the purple membrane absorption spectrum. Photochem Photobiol (1984) 2.42
Quinolone-resistant mutants of escherichia coli DNA topoisomerase IV parC gene. Antimicrob Agents Chemother (1996) 2.42
Interplay between efflux pumps may provide either additive or multiplicative effects on drug resistance. J Bacteriol (2000) 2.41
Expression of heme oxygenase-1 can determine cardiac xenograft survival. Nat Med (1998) 2.40
Induction of the transcription factor IRF-1 and interferon-beta mRNAs by cytokines and activators of second-messenger pathways. Proc Natl Acad Sci U S A (1989) 2.38
Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum (2012) 2.37
Identification and partial characterization of Mycobacterium avium and Mycobacterium intracellulare by using DNA probes. J Clin Microbiol (1989) 2.37
IL-18, although antiallergic when administered with IL-12, stimulates IL-4 and histamine release by basophils. Proc Natl Acad Sci U S A (1999) 2.35
Norfloxacin resistance in a clinical isolate of Escherichia coli. Antimicrob Agents Chemother (1987) 2.33
Purification, induction, and distribution of placental glutathione transferase: a new marker enzyme for preneoplastic cells in the rat chemical hepatocarcinogenesis. Proc Natl Acad Sci U S A (1985) 2.32
Chronic inflammatory arthropathy associated with HTLV-I. Lancet (1989) 2.28
Functional expression and germline transmission of a human chromosome fragment in chimaeric mice. Nat Genet (1997) 2.28
Properties of a new penicillinase type produced by Bacteroides fragilis. Antimicrob Agents Chemother (1982) 2.27
A new technique for monitoring the behaviour of free-ranging Adélie penguins. J Exp Biol (2001) 2.24
Position of immobilization after dislocation of the glenohumeral joint. A study with use of magnetic resonance imaging. J Bone Joint Surg Am (2001) 2.24
Mapping of brain acetylcholinesterase alterations in Lewy body disease by PET. Neurology (2009) 2.23
Organizing and computing metabolic pathway data in terms of binary relations. Pac Symp Biocomput (1997) 2.19
Induction of inflammatory arthropathy resembling rheumatoid arthritis in mice transgenic for HTLV-I. Science (1991) 2.18
Defective beta adrenergic response of cystic fibrosis sweat glands in vivo and in vitro. J Clin Invest (1984) 2.17
Immune cell activation by bacterial CpG-DNA through myeloid differentiation marker 88 and tumor necrosis factor receptor-associated factor (TRAF)6. J Exp Med (2000) 2.16
Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBFbeta. Cell (2001) 2.15
Clear cell change in colorectal adenomas: its incidence and histological characteristics. Histopathology (1999) 2.15
Reevaluation of the thyroidal radioactive iodine uptake test, with special reference to reversible primary hypothyroidism with elevated thyroid radioiodine uptake. J Clin Endocrinol Metab (1988) 2.15
Penguin-mounted cameras glimpse underwater group behaviour. Proc Biol Sci (2004) 2.15
Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob Agents Chemother (1999) 2.11
Biochemical properties of beta-lactamase produced by Legionella gormanii. Antimicrob Agents Chemother (1986) 2.10
Glutathione transferases and cancer. Crit Rev Biochem Mol Biol (1992) 2.09
In vitro antimycobacterial activities of newly synthesized benzoxazinorifamycins. Antimicrob Agents Chemother (1991) 2.08
The structure of bacteriorhodopsin at 3.0 A resolution based on electron crystallography: implication of the charge distribution. J Mol Biol (1999) 2.07
Impact of siderophore production on Pseudomonas aeruginosa infections in immunosuppressed mice. Infect Immun (2000) 2.05
Cellular responses to bacterial cell wall components are mediated through MyD88-dependent signaling cascades. Int Immunol (2000) 2.05
Inhibition of DNA gyrase by optically active ofloxacin. Antimicrob Agents Chemother (1987) 2.03
Snail and SIP1 increase cancer invasion by upregulating MMP family in hepatocellular carcinoma cells. Br J Cancer (2004) 2.03
Precise monitoring of porpoising behaviour of Adélie penguins determined using acceleration data loggers. J Exp Biol (1999) 2.00
Interaction of sphingosine 1-phosphate with plasma components, including lipoproteins, regulates the lipid receptor-mediated actions. Biochem J (2000) 2.00
VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration. Cell Death Differ (2001) 2.00
Synthesis and antibacterial activities of substituted 7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxyl ic acids. Chem Pharm Bull (Tokyo) (1984) 1.99
Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem (2001) 1.98
Involvement of a cis-element that binds an H2TF-1/NF kappa B like factor(s) in the virus-induced interferon-beta gene expression. Nucleic Acids Res (1989) 1.97
Control of glucose utilization in working perfused rat heart. J Biol Chem (1994) 1.97
Purification of Citrobacter freundii DNA gyrase and inhibition by quinolones. Antimicrob Agents Chemother (1988) 1.93
Inhibition by quinolones of DNA gyrase from Staphylococcus aureus. Antimicrob Agents Chemother (1991) 1.93
Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A (1993) 1.92
Knockout of the Sendai virus C gene eliminates the viral ability to prevent the interferon-alpha/beta-mediated responses. FEBS Lett (1999) 1.92
PR39, a peptide regulator of angiogenesis. Nat Med (2000) 1.90
Chemotherapeutic efficacy of a newly synthesized benzoxazinorifamycin, KRM-1648, against Mycobacterium avium complex infection induced in mice. Antimicrob Agents Chemother (1992) 1.89
A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene (1997) 1.88
A specific DNA sequence controls termination of transcription in the gastrin gene. Mol Cell Biol (1986) 1.88
Mechanism of quinolone resistance in Staphylococcus aureus. J Infect Chemother (2000) 1.88
Human macrophage scavenger receptors: primary structure, expression, and localization in atherosclerotic lesions. Proc Natl Acad Sci U S A (1990) 1.87
Antimicrobial activity of DV-7751a, a new fluoroquinolone. Antimicrob Agents Chemother (1993) 1.86